1,2,4‐Triazole and benzimidazole fused dihydropyrimidine derivatives: Design, green synthesis, antibacterial, antitubercular, and antimalarial activities
Archiv der Pharmazie · 2023-04 · 356 (4)
DOI: 10.1002/ardp.202200545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 19.12.2022. Verfasst von Jaydeep A Mokariya und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Sardar Patel University, Anand, Gujarat, India. Hauptthemen laut MEDLINE: Antimalarials, Anti-Infective Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
This study reports the design and synthesis of novel 1,2,4‐triazolo/benzimidazolo‐pyrimidine linked 1‐benzyl‐4‐[( p ‐tolyloxy)methyl]‐1,2,3‐triazole derivatives as potent antimicrobial agents according to their in vitro antibacterial, antifungal, antitubercular as well as antimalarial activities. An efficient, ecologically benign, and facile multicomponent synthesis was employed to synthesize these derivatives. The synthesis is accelerated with the mild and eco‐friendly organocatalyst tetrabutylammonium bromide, providing a yield of 82%–96% within the short reaction time of 0.5–1.5 h. Compared with the MIC values of ciprofloxacin and ampicillin on the respective strains, compound d2 showed better activity against Escherichia coli and Streptococcus pyogenes and compound d8 showed better MIC against Staphylococcus aureus . Additionally, compounds d3 , d4 , and d5 showed potent MIC values against Pseudomonas aeruginosa . All triazolo‐pyrimidine derivatives d1–d8 showed potent inhibitory action against Gram‐positive strains. Compound e3 showed good potency against Mycobacterium tuberculosis H37Rv. The IC 50 values of d3 and e2 indicated better activity against Plasmodium falciparum . Collectively, these derivatives depict potent multifaceted activity and provide promising access for further antimicrobial and antimalarial investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Sardar Patel University, Anand, Gujarat, India.
- Microcare Laboratory and Tuberculosis Research Centre, Haripura, Surat, Gujarat, India.
Förderung
- None
Zitieren
APA
Mokariya, J. A., Rajani, D. P., & Patel, M. P. (2023). 1,2,4‐Triazole and benzimidazole fused dihydropyrimidine derivatives: Design, green synthesis, antibacterial, antitubercular, and antimalarial activities. Archiv der Pharmazie, 356(4). https://doi.org/10.1002/ardp.202200545
Vancouver
Mokariya JA, Rajani DP, Patel MP. 1,2,4‐Triazole and benzimidazole fused dihydropyrimidine derivatives: Design, green synthesis, antibacterial, antitubercular, and antimalarial activities. Archiv der Pharmazie. 2023;356(4). doi:10.1002/ardp.202200545
BibTeX
@article{Mokariya2023,
author = {Mokariya, Jaydeep A and Rajani, Dhanji P and Patel, Manish P},
title = {1,2,4‐Triazole and benzimidazole fused dihydropyrimidine derivatives: Design, green synthesis, antibacterial, antitubercular, and antimalarial activities},
journal = {Archiv der Pharmazie},
year = {2023},
volume = {356},
number = {4},
doi = {10.1002/ardp.202200545}
}
EUVIMED